Free Trial
NASDAQ:TERN

Terns Pharmaceuticals (TERN) Stock Price, News & Analysis

Terns Pharmaceuticals logo
$4.53 +0.53 (+13.25%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$4.51 -0.02 (-0.33%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Terns Pharmaceuticals Stock (NASDAQ:TERN)

Key Stats

Today's Range
$3.95
$4.57
50-Day Range
$2.78
$4.53
52-Week Range
$1.87
$11.40
Volume
1.42 million shs
Average Volume
1.47 million shs
Market Capitalization
$395.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.63
Consensus Rating
Moderate Buy

Company Overview

Terns Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

TERN MarketRank™: 

Terns Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 241st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Terns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Terns Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Terns Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Terns Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Terns Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Terns Pharmaceuticals has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Terns Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    8.94% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 9.19%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Terns Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Terns Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.94% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 9.19%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Terns Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Terns Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    12 people have searched for TERN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Terns Pharmaceuticals insiders have bought 5,022.87% more of their company's stock than they have sold. Specifically, they have bought $186,575.00 in company stock and sold $3,642.00 in company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Terns Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Terns Pharmaceuticals' insider trading history.
Receive TERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TERN Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

TERN Stock Analysis - Frequently Asked Questions

Terns Pharmaceuticals' stock was trading at $5.54 on January 1st, 2025. Since then, TERN shares have decreased by 18.2% and is now trading at $4.53.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03.

Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

Last Earnings
5/08/2025
Today
7/09/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TERN
CIK
1831363
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$7.50
Potential Upside/Downside
+244.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.85 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
1.11

Miscellaneous

Free Float
86,027,000
Market Cap
$395.65 million
Optionable
Not Optionable
Beta
-0.11
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:TERN) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners